PT - JOURNAL ARTICLE AU - Zhang, Yu AU - Cao, Shuo AU - Niu, Nan AU - Shan, Huilian AU - Xue, Jinqi AU - Chen, Guanglei AU - Xu, Yongqing AU - Yin, Jianqiao AU - Liu, Chao AU - Sun, Lisha AU - Jiang, Xiaofan AU - Tang, Meiyue AU - Xu, Qianshi AU - Jia, Mingxuan AU - Zhang, Xu AU - Zhang, Zhenyong AU - Zhang, Qingfu AU - Wang, Jianfei AU - Li, Ailin AU - Yang, Yongliang AU - Liu, Caigang TI - Efficacy and safety of neoadjuvant stereotactic body radiation therapy plus dalpiciclib and exemestane for hormone receptor-positive, HER2-negative breast cancer: A prospective pilot study AID - 10.1101/2024.08.31.24312890 DP - 2024 Jan 01 TA - medRxiv PG - 2024.08.31.24312890 4099 - http://medrxiv.org/content/early/2024/09/01/2024.08.31.24312890.short 4100 - http://medrxiv.org/content/early/2024/09/01/2024.08.31.24312890.full AB - Background Both neoadjuvant chemotherapy and endocrine therapy only result in trivial pathological complete response rates and moderate objective response rates (ORR) in hormone receptor (HR)-positive, human epidermal growth factor receptor-2 (HER2)-negative breast cancer, more promising alternatives are urgently needed. With proven synergistic effect of cyclin dependent kinase 4/6 (CDK4/6) inhibitor and radiotherapy in preclinical studies, this pilot study aimed to explore the efficacy and safety of neoadjuvant stereotactic body radiation therapy (SBRT) followed by dalpiciclib and exemestane in HR-positive, HER2-negative breast cancer.Methods This was a single-arm, non-controlled prospective pilot study. Treatment-naïve patients with unilateral HR-positive, HER2-negative breast cancer received neoadjuvant radiotherapy (24Gy/3F) followed by dalpiciclib and exemestane for 6 cycles. The primary endpoint was the proportion of patients with residual cancer burden (RCB) score of 0-I. Key secondary endpoints included ORR, biomarker analysis, and safety.Results All 12 enrolled patients completed the study treatment and surgery. Two (16.7%) of them achieved the RCB 0-I with the ORR of 91.7% (11/12). Analyses of tumor specimens showed significant increase of infiltrating T cells rather than alteration of PD-L1 positive immune cells. The most common grade 3 adverse events (AEs) were neutropenia (66.7%) and leukopenia (25.0%), but no grade 4-5 AE or death occurred.Conclusions Our results suggested neoadjuvant SBRT followed by dalpiciclib and exemestane are effective and tolerable, and provides novel insights for the neoadjuvant treatment of HR+/HER2-breast cancer, which may be considered as an alternative to patients with HR-positive, HER2-negative breast cancer.Competing Interest StatementJianfei Wang is the employee of Jiangsu Hengrui Pharmaceuticals Co., Ltd. No other potential conflicts of interest were reported.Clinical TrialNCT05132790Funding StatementThis research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:the Institutional Review Board and Ethics Committee of Shengjing Hospital of China Medical UniversityI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Not Applicable